Skip to content
OpenCapital
Get started

Twist Bioscience Corporation TWST Cash And Cash Equivalents And Short Term Investments Amortized Cost

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$5.45B+24.4%
Enterprise value$5.44B+30.4%
P/S13.3×+0.7×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept twst:CashAndCashEquivalentsAndShortTermInvestmentsAmortizedCost.

The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's cash and cash equivalents and short term investments amortized cost.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Twist Bioscience Corporation's cash and cash equivalents and short term investments amortized cost?
Twist Bioscience Corporation (TWST) reported cash and cash equivalents and short term investments amortized cost of $171.67M in Q1 2026.
How has Twist Bioscience Corporation's cash and cash equivalents and short term investments amortized cost changed year-over-year?
Twist Bioscience Corporation's cash and cash equivalents and short term investments amortized cost decreased by 33.6% year-over-year, from $258.65M to $171.67M.
What is the long-term trend for Twist Bioscience Corporation's cash and cash equivalents and short term investments amortized cost?
Over 3 years (2022 to 2025), Twist Bioscience Corporation's cash and cash equivalents and short term investments amortized cost has grown at a -22.9% compound annual growth rate (CAGR), from $506.56M to $232.37M.